Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hepatitis C virus Core Antigen as a predictor of non-response in genotype 1 chronic hepatitis C patients treated with peginterferon alpha-2b plus ribavirin.

Journal of hepatology - 1 Mar 2004

Buti Maria, Mendez Claudia, Schaper Melanie, Sauleda Silvia, Valdes Auristela, Rodriguez-Frias Francisco, Jardi Rosendo, Esteban Rafael

Abstract excerpt

BACKGROUND/AIMS: Chronic hepatitis C patients infected by genotype 1 are the least responsive to combination therapy and therefore monitoring response is important in identifying non-responders quickly, permitting therapy discontinuation and avoiding side effects and costs. We examined the usefulness of measuring total HCV Core Ag in early treatment with peginterferon alpha-2b and ribavirin in genotype 1 patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Therapy, Combination
Share to Hepatitis C, Chronic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Osmolar Concentration

Share to Polyethylene Glycols

Share to Ribavirin

Share to Viral Core Proteins

Source

Identifiers

PMID: 15123370
DOI: 10.1016/j.jhep.2003.11.026

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hepatitis C virus Core Antigen as a predictor of non-response in genotype 1 chronic hepatitis C patients treated with peginterferon alpha-2b plus ribavirin.PMID 15123370Read ↗

Early predictive efficacy of core antigen on antiviral outcomes in genotype 1 hepatitis C virus infected patients.Semantic proximity Read ↗

Clinical utility of the ARCHITECT HCV Ag assay for early treatment monitoring in patients with chronic hepatitis C genotype 1 infection.Semantic proximity Read ↗

Review article: indicators and predictors of response to anti-viral therapy in chronic hepatitis C.Semantic proximity Read ↗

Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy.Semantic proximity Read ↗

Viral kinetics during the first month of treatment in patients with genotype 1 chronic hepatitis C.Semantic proximity Read ↗

Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.Semantic proximity Read ↗

Predictive baseline criteria of primary therapeutic failure in chronic hepatitis C genotype 1.Semantic proximity Read ↗

Factors predictive of a beneficial response to therapy of hepatitis C.Semantic proximity Read ↗

Early decline of the HCV core antigen can predict SVR in patients with HCV treated by Pegylated interferon plus ribavirin combination therapy.Semantic proximity Read ↗

Response-guided therapy in patients with genotype 1 hepatitis C virus: current status and future prospects.Semantic proximity Read ↗

Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison.Semantic proximity Read ↗

Risk score based PEG Interferon alpha 2b and Ribavirin treatment response estimation model for genotype 1 chronic hepatitis C patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.